Accentia, Inc., Biovest International, Inc. Emerges from Chapter 11 Reorganization
11/17/2010 6:57:55 AM
More...
|
Accentia, Inc. Files Plan of Reorganization; Restructuring Supports Plans to Advance Promising Multiple Sclerosis Therapy into Late-Stage Clinical Trial
6/1/2010 6:29:18 AM
More...
|
Accentia, Inc.'s CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients
1/7/2008 8:31:22 AM
More...
|
Accentia, Inc. Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
10/8/2007 8:09:34 AM
More...
|
Accentia, Inc. Says Interim Data on SinuNase Promising
6/28/2007 10:05:38 AM
More...
|
FDA Gives Permission To Use Very Sensitive Molecular Evidence Of Cancer In BiovaxID Pivotal Phase 3: Company Intends To Use Blood Test To File Application For Accelerated Approval
5/16/2006 12:53:14 PM
More...
|
Accentia, Inc. Says Cancer Vaccine Raises Survival, Shares Up
1/24/2006 10:23:51 AM
More...
|
Accentia Biopharmaceuticals Licenses Targeted Technology For Treatment Of Chronic Rhinosinusitis (CRS): 37 Million Affected In The US And No Approved Pharmaceutical
10/19/2005 5:10:54 PM
More...
|
BioDelivery Sciences International (BDSI) Announces $2,500,000 Asset Sale To Accentia, Inc.
10/19/2005 5:10:19 PM
More...
|
PPD, Inc. (PPDI) Makes Equity Investment In Accentia, Inc.
10/19/2005 5:09:55 PM
More...
|
|